WO2006062094A1 - 新規癌抗原ペプチド及びその用途 - Google Patents
新規癌抗原ペプチド及びその用途 Download PDFInfo
- Publication number
- WO2006062094A1 WO2006062094A1 PCT/JP2005/022369 JP2005022369W WO2006062094A1 WO 2006062094 A1 WO2006062094 A1 WO 2006062094A1 JP 2005022369 W JP2005022369 W JP 2005022369W WO 2006062094 A1 WO2006062094 A1 WO 2006062094A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- peptide
- amino acid
- cells
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a protein specific to human cancer, a partial peptide thereof, and use thereof. Furthermore, the present invention relates to a polynucleotide encoding the peptide, activated T cells stimulated and induced by the peptide, an antigen-presenting cell containing a complex of the peptide and an HLA molecule, an antibody against the peptide, and the It relates to medicines containing peptides or antibodies.
- Cancer is the leading cause of all deaths, and the current treatment is a combination of radiation therapy and chemotherapy, mainly surgery. Despite the recent development of new surgical methods and the discovery of new anti-cancer drugs, the therapeutic results for cancer, except for some cancers, have improved significantly.
- Non-Patent Document 1 In 1991, Boon et al. From Ludwig Laboratories in Belgium isolated human melanoma antigen MAGE1 recognized by CD8 positive T cells by cDNA expression cloning using autologous cancer cell lines and cancer-reactive T cells (Non-patent Document 2). See). After Boon, tyrosinase (see Non-Patent Document 3), MARTlZMelanA (see Non-Patent Document 4), gplOO (See Non-Patent Document 5), etc. were isolated as antigens recognized by CD8 + T cells .
- a protein recognized as an antigen is excessively present in a few cancer cells compared to normal cells.
- antigen-specific helper ⁇ cells that assist in the activity of cytotoxic ⁇ cells are induced. It would also be desirable to include a peptide moiety that can be.
- YKL-40 has been used as a tumor marker in serum related to human malignant brain tumors. The possibility of being able to do is suggested. This protein has been reported to be overexpressed in most human malignant brain tumors, while this protein is almost expressed in normal brain tissue.
- Non-Patent Document 1 Akiyoshi Satoshi, “Cancer and Cancer Chemotherapy”, 1997, 24th, p551—519
- Non-patent document 2 Bruggen P. et al., Science, 254: 1643-1647 (1991)
- Non-patent document 3 Robbins P. F. et al., Cancer Res., 54: 3124-3126 (1994)
- Non-Patent Document 4 Kawakami Y. et al., Proc. Natl. Acad. Sci. USA, 91 (9): 3515-3519 (1994)
- Non-Patent Document 5 Kawakami Y. et al., Proc. Natl. Acad. Sci. USA, 91: 6 458-6462 (1994)
- Non-Patent Document 6 Meena K. et al., Cancer Res., 62: 4364-4368 (2002) Disclosure of the Invention
- An object of the present invention is to provide a novel peptide useful as a therapeutic and Z or prophylactic agent for cancer. Another object of the present invention is to provide use of the peptide as a cancer therapeutic and Z or prophylactic agent and a therapeutic agent for treating antigen-presenting cells. Furthermore, the object of the present invention is to treat isolated antigen-presenting cells containing the complex of the peptide and HLA molecule, and isolated T cells that selectively bind the complex of peptide and HLA molecule, and treatment of these cancers. And to provide Z or prophylactic use.
- the inventors of the present application have presented a partial peptide present in a specific region in YKL-40 having the amino acid sequence represented by SEQ ID NO: 2 by antigen-presenting cells, It has the ability to activate and proliferate and proliferate cytotoxic T cells specific to the peptide (immunity-inducing activity), so that the peptide is therapeutic and Z or prevention of cancer, and it is in contact with the peptide
- the present invention was completed by discovering that the antigen-presenting cells and T cells in contact with the antigen-presenting cells were cancer treatment and Z or prevention.
- the present invention relates to 7 or more amino acid sequences represented by SEQ ID NO: 2 in the sequence listing.
- a peptide consisting of consecutive amino acids, the region of aal0-19, aa49-61, aa74-83, aa96-117, aal52-161, aal77-185, aa202-211, aa246-261 or aa326-354 of SEQ ID NO: 2 Peptides having a contiguous amino acid sequence and having immunity-inducing activity, or peptides having 7-30 amino acid residues having immunity-inducing activity having 80% or more identity with any of these!
- a peptide comprising any of the above peptides as a partial sequence and having 8 to 31 amino acid residues and having immunity-inducing activity.
- the present invention also provides a polynucleotide encoding the peptide of the present invention.
- this invention provides the pharmaceutical which contains the peptide of the said invention as an active ingredient.
- the present invention provides a therapeutic and Z or preventive agent for cancer comprising the peptide of the present invention as an active ingredient.
- the present invention provides the use of the peptide of the present invention for producing a therapeutic and / or preventive agent for cancer.
- the present invention provides a method for treating and / or preventing cancer comprising administering to an individual an effective amount of the peptide of the present invention.
- this invention provides the processing agent of an antigen presentation cell containing the peptide of the said invention. Furthermore, the present invention provides the use of the peptide of the present invention for the production of a treatment for antigen-presenting cells. Furthermore, the present invention provides a method for treating an antigen-presenting cell, which comprises contacting the peptide of the present invention with the antigen-presenting cell. Furthermore, the present invention provides an isolated antigen-presenting cell comprising a complex of the above-described peptide of the present invention and an HLA molecule. Furthermore, the present invention provides a method for activating T cells, which comprises contacting the isolated antigen-presenting cells of the present invention with T cells.
- the present invention provides an isolated T cell that selectively binds the complex of the peptide of the present invention and an HLA molecule. Furthermore, the present invention provides a medicament containing the isolated antigen-presenting cell of the present invention or the isolated T cell of the present invention as an active ingredient. Furthermore, the present invention provides a therapeutic and Z or preventive agent for cancer comprising the isolated antigen-presenting cell of the present invention or the isolated T cell of the present invention as an active ingredient. Furthermore, the present invention provides a method for treating and / or preventing cancer, comprising administering an effective amount of the isolated antigen-presenting cell of the present invention or the isolated T cell of the present invention.
- the present invention provides an antibody or antigen-binding fragment thereof that undergoes an antigen-antibody reaction with the peptide of the present invention. Furthermore, the present invention provides a diagnostic agent for cancer comprising the antibody of the present invention or an antigen-binding fragment thereof. Furthermore, the present invention provides the antibody of the present invention or an antigen thereof Provided is a therapeutic and / or prophylactic agent for cancer comprising a binding fragment. Furthermore, the present invention provides a protein having the amino acid sequence represented by SEQ ID NO: 2 or a protein having an amino acid sequence having 80% or more identity with the amino acid sequence, and having a protein having immunity-inducing activity as an active ingredient. A cancer-specific immunity-inducing agent is provided.
- a novel peptide useful for cancer treatment and Z or prevention, and induction of antigen-presenting cells and ⁇ cells therefor, and various uses of the peptide in the medical field are provided.
- CD8 positive T cells activated by the peptide of the present invention exhibit excellent cytotoxic activity against cancer cells expressing YKL-40. Therefore, the peptide of the present invention is effective for the treatment and Z or prevention of cancer by administering it to humans or using it to administer activated T cells to humans in vitro.
- FIG. 1 shows that peptide-specific CD8-positive T cells recognize a complex of the peptide and HLA-A0201 and produce IFN- ⁇ .
- FIG. 2 is a diagram showing the damage activity of peptide-specific CD8-positive sputum cells against cancer cells.
- FIG. 3 is a diagram showing that peptide-specific CD4-positive sputum cells recognize a complex of the peptide and HLA-DRB1 * 04 and produce IFN- ⁇ .
- FIG. 4 shows that peptide-specific CD4-positive sputum cells proliferate in response to rodent cells that have engulfed lysates of cancer cells.
- FIG. 5 is a diagram showing that peptide-specific CD8-positive sputum cells recognize a complex of the peptide and HLA-A0201 and produce IFN- ⁇ .
- FIG. 6 is a diagram showing the damage activity of peptide-specific CD8-positive sputum cells against cancer cells.
- FIG. 7 is a diagram showing the damage activity of peptide-specific CD8-positive sputum cells against cancer cells. Best form for [0012] As described above, as the peptide of the present invention, first, a peptide having 7 or more consecutive amino acid forces in the amino acid sequence (amino acid sequence of YKL-40) represented by SEQ ID NO: 2 in the Sequence Listing.
- aa indicates the amino acid residue of the amino acid sequence, counting the N-terminal force.
- aal0 indicates that the N-terminal force is the 10th amino acid residue
- aal0-l 9 region is the 19th amino acid residue from the 10th amino acid residue. A region consisting of 10 amino acid residues up to amino acid residues is shown.
- immuno-inducing activity means the ability to activate and proliferate T cells that react with cancer cells expressing YKL-40, and is specifically measured by the method described in detail in the Examples below.
- T cells IFN- ⁇ production capacity and cytotoxic activity against Z or YKL-40 expressing cancer cells higher than control T cells not stimulated with peptide and stimulated with peptide This means that T cells proliferate better than control T cells when stimulated with peptides! /. Proliferation can be confirmed by visual observation, counting the number of cells under a microscope, flow cytometry, the amount of tritium thymidine in the medium taken into the cells, and the like.
- the measurement of IFN- ⁇ production ability employed in the following Examples is described in, for example, ⁇ . Immunol., 154, p2257, 1995, and the measurement of cytotoxic activity is performed in Int. J. Cancer, 58 : p317, 1994), which is in accordance with a known method called 51 Cr release assembly.
- Preferable examples of the peptide of the present invention include peptides having the amino acid sequences shown in SEQ ID NO: 3 to SEQ ID NO: 19.
- the sequence numbers, amino acid sequences, and positions in SEQ ID NO: 2 of these peptides are shown in Table 1 below.
- “having an amino acid sequence” means that amino acid residues are arranged in such an order. Therefore, for example, “a peptide having the amino acid sequence represented by SEQ ID NO: 3” means a Phe Gly Ser Gin Arg Phe Ser Lys He Ala Ser Asn Thr Gin Ser Arg Arg amino acid sequence having a size of 17 amino acid residues. Means peptide. Further, for example, “a peptide having the amino acid sequence represented by SEQ ID NO: 3” may be abbreviated as “a peptide of SEQ ID NO: 3”. is there.
- peptide of the present invention one to several amino acid residues are substituted, deleted and Z or inserted, and have 80% or more, preferably 90% or more identity with the original peptide.
- a peptide having 7 to 30 amino acid residues hereinafter sometimes referred to as “immune-inducing modified peptide” for convenience
- immune-inducing modified peptide having immunity-inducing activity
- the “identity” of amino acid sequences means that both amino acid sequences are aligned so that as many amino acid residues as possible match (insert a gap if necessary).
- the 20 amino acids that make up natural proteins are neutral amino acids with low polarity side chains (Gly, lie, Val, Leu, ala, Met, Pro), and neutral amino acids with hydrophilic side chains. (Asn, Gin, Thr, Ser, Tyr Cys), acidic amino acids (Asp, Glu), basic amino acids (Arg, Lys, His), aromatic amino acids (Phe, Tyr, Trp) It is known that the properties of the peptide often do not change if substitution is made between these groups. Therefore, when the amino acid residue in the immunity-inducing partial peptide of the present invention is substituted, it is highly possible that the immunity-inducing activity can be maintained by substitution between these groups.
- the peptide of the present invention described above is included as a partial sequence (that is, another peptide is added to one or both ends of the peptide of the present invention.
- a peptide having 8 to 31 amino acid residues and having immunity-inducing activity (hereinafter sometimes referred to as “immunity-inducing additional peptide” for convenience) as well as the peptide of the present invention. It can be used for the treatment and Z or prevention of cancer, and is included in the scope of the present invention.
- the peptide of the present invention described above can be easily prepared by a conventional method using a commercially available peptide synthesizer.
- the present invention provides a polynucleotide encoding the peptide of the present invention.
- Polynucleotides can be DNA or RNA! / ⁇ .
- conservative substitution base sequences can be used.
- the base sequence of a polynucleotide encoding a specific amino acid sequence can be easily specified. Therefore, the nucleotide sequence of the polynucleotide encoding the immunity-inducing modified peptide and immunity-inducing added peptide of the present invention can also be easily specified.
- These polynucleotides can be synthesized by a conventional method using a commercially available nucleic acid synthesizer.
- the present invention also provides a recombinant vector comprising the above-described polynucleotide of the present invention and capable of expressing the polynucleotide in a cell.
- the cell may be a mammalian cell or a prokaryotic or eukaryotic microorganism such as E. coli or yeast.
- a vector for introducing a gene into a mammalian cell a plasmid vector or a viral vector may be used. These are well known and various types are commercially available. can do.
- the recombinant vector of the present invention can be obtained by inserting the above-described polynucleotide of the present invention into the multicloning site of a commercially available vector.
- a thread-replaceable vector in which the polynucleotide of the present invention is incorporated into a vector for gene transfer into mammalian cells can be used as a gene vaccine for cancer treatment and Z or prevention.
- the administration route of the gene vaccine is preferably a parenteral administration route such as intramuscular administration, subcutaneous administration, intravenous administration or intraarterial administration, and the dosage can be appropriately selected according to the type of antigen and the like.
- the weight of the gene vaccine is about 0.1 ⁇ g to 100 mg, preferably about 1 ⁇ g to 10 mg per kg body weight.
- Examples of methods using viral vectors include retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, vaccinia viruses, box viruses, polioviruses, Sindbis viruses, and other RNA viruses or DNA viruses.
- DNA can be incorporated and introduced.
- methods using retroviruses, adenoviruses, adeno-associated viruses, vaccinia viruses, etc. are particularly preferred.
- Examples of other methods include a method in which an expression plasmid is directly administered into a muscle (DNA-cutting method), a ribosome method, a lipofectin method, a microinjection method, a calcium phosphate method, an electopore position method, and the like.
- the vaccine method and ribosome method are preferred.
- an in vivo method When administered by an in vivo method, it can be administered by an appropriate administration route according to the disease or symptom to be treated. For example, it can be administered intravenously, artery, subcutaneously, intramuscularly. When administered by an in vivo method, for example, it can be in the form of a preparation such as a liquid, but is generally an injection containing the DNA of the present invention, which is an active ingredient, and is used as required.
- the carrier may be arranged.
- a ribosome containing the DNA of the present invention or Membrane fusion ribosomes can be in the form of ribosome preparations such as suspending agents, freezing agents, and centrifugal concentrating freezing agents.
- vectors for microorganisms such as Escherichia coli and yeast are also well known, and various types are commercially available.
- a recombinant vector obtained by incorporating the polynucleotide of the present invention into a vector for microorganisms can be used for mass production of the peptide of the present invention by genetic engineering.
- the integration of the recombinant vector into the microorganism can be performed by a well-known method.
- the peptide of the present invention exhibits immunity-inducing activity. That is, T cells stimulated with the peptide of the present invention exhibit cytotoxic activity against cancer cells expressing YKL-40 and proliferate. Therefore, cancer can be treated and Z or prevented by administering the peptide of the present invention to a living body. That is, the present invention provides a medicament containing the peptide of the present invention as an active ingredient and a therapeutic and Z or preventive agent for cancer containing the peptide of the present invention as an active ingredient.
- cancers to be treated with the cancer treatment and Z or preventive agent of the present invention include cancers expressing YKL-40, and include squamous epithelium of brain tumor, head, neck, lung, uterus or esophagus. Examples include cancer, melanoma, lung or uterine adenocarcinoma, and renal cancer. Further, the administration subject is a mammal, and human is particularly preferable.
- the therapeutic route of cancer containing the peptide of the present invention as an active ingredient and the administration route of Z or preventive agent may be oral administration or parenteral administration, but intramuscular administration, subcutaneous administration, intravenous administration, intraarterial administration. Such parenteral administration is preferred.
- the dose is appropriately selected according to the symptoms, purpose of use, etc. as long as it is an amount effective for cancer treatment and Z or prevention, but is usually 0.0001 mg to 1000 mg, preferably O.OOlmg. ⁇ 1000 mg, preferably administered once every few days or months.
- the therapeutic and Z or preventive agent for cancer containing the peptide of the present invention as an active ingredient should be formulated using a pharmacologically acceptable carrier and Z or diluent suitable for each dosage form.
- a pharmacologically acceptable carrier and Z or diluent suitable for each dosage form should be formulated using a pharmacologically acceptable carrier and Z or diluent suitable for each dosage form.
- Can do Formulation methods and various carriers therefor are well known in the field of pharmaceutical formulations.
- Pharmacologically acceptable carriers or diluents include, for example, buffer solutions such as physiological buffers and excipients (sugar, lactose, corn starch, calcium phosphate, sorbitol, darting (E.g., syrup, gelatin, gum arabic, sorbitol, polyvinyl chloride, tragacanth, etc.), lubricant (magnesium stearate, polyethylene glycol, talc, silica, etc.) May be.
- buffer solutions such as physiological buffers and excipients (sugar, lactose, corn starch, calcium phosphate, sorbitol, darting (E.g., syrup, gelatin, gum arabic, sorbitol, polyvinyl chloride, tragacanth, etc.), lubricant (magnesium stearate, polyethylene glycol, talc, silica, etc.) May be.
- examples of the dosage form include oral preparations such as tablets, capsules,
- the above-mentioned cancer therapeutic and Z or preventive agent containing the peptide of the present invention as an active ingredient may be in the form of a vaccine.
- an adjuvant in addition to the active ingredient.
- Adjuvants can enhance the immunological response by providing a reservoir of antigen (extracellular or in macrophages), activating macrophages and stimulating specific sets of lymphocytes. Many types of adjuvants are well known in the art.
- MPL SmithKline Beecham
- QS21 SmithKline Bee cham
- Quillja saponaria extract QA—21 saponin PCT application WO 96/33739 [DQS21 described here; QS—7, QS—17, QS—18 and QS—L1 (So, outside 10 persons, “Molecules' Molecules and cells, 1997, VII, p.
- the peptide is administered mixed with the DQS21 / M PL combination.
- the ratio of DQS21 to MPL is typically about 1:10 to: L0: 1, preferably about 1: 5 to 5: 1, more preferably about 1: 1.
- DQS21 and MPL are present in the vaccine formulation in the range of about 1 g to about 100 ⁇ g.
- Other adjuvants are known in the art and can be used in the present invention (eg, “Monoclonal Antibodies: Principles and Practice” by Goding, “Monoclonal Antibodies: Principole Nore, Ant Fuchuk” 7 ”chairs). ) ", 2 / 3 ⁇ 4 ⁇ , 1 986).
- Preparation of peptide and adjuvant mixture or emulsion The methods are well known to those skilled in vaccination.
- IL — 12 interleukins 12
- GM-CSF GM-CSF
- IL-18 Flt3 ligand
- the therapeutic compositions of the present invention are administered in a pharmaceutically acceptable preparation.
- Such preparations routinely contain pharmaceutically acceptable concentrations of salts, buffers, preservatives, compatible carriers, adjuvant immunity enhancing agents such as adjuvants and cytodynamics, and optionally other therapeutic agents. It can be contained in.
- the peptide of the present invention is presented to the antigen-presenting cell by contacting the peptide of the present invention with the antigen-presenting cell in vitro. be able to. That is, the present invention also provides a treatment agent for antigen presenting cells, comprising the peptide of the present invention.
- antigen-presenting cells rod cells or B cells carrying HLA class I or HLA class II molecules can be preferably used.
- HLA class I and HLA class II molecules have been identified and are well known. Examples of HLA class I molecules include HLA-A, HLA-B, and HLA-C.
- HLA class II molecules include HLA-DR, HL A-DQ, and HLA-DP.
- Spider cells or B cells carrying HLA class I or HLA class II molecules can also be prepared for peripheral blood force by known methods.
- a rod-shaped cell is induced from bone marrow, umbilical cord blood, or patient's peripheral blood using granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-3 (Yes! / Is IL-4), and its culture system Tumor-specific rod cells can be induced by adding a tumor-related peptide to.
- GM-CSF granulocyte-macrophage colony-stimulating factor
- IL-3 granulocyte-macrophage colony-stimulating factor
- Tumor-specific rod cells can be induced by adding a tumor-related peptide to.
- the cells used can be bone marrow or umbilical cord blood provided by a healthy person, the patient's own bone marrow or peripheral blood, etc.
- Peripheral blood or bone marrow can be a fresh sample, a cryopreserved sample, or a cryopreserved sample.
- whole blood may be cultured, or only leukocyte components may be separated and cultured, but the latter is more efficient and preferable.
- mononuclear cells may be separated among the leukocyte components.
- the entire cells constituting the bone marrow may be cultured, or mononuclear cells may be separated and cultured from this.
- Peripheral blood, its white blood cell components, and bone marrow cells contain mononuclear cells, hematopoietic stem cells or immature rod cells, CD4 positive cells, and the like that are the source of rod cells.
- the site force-in used may be of any natural type or genetically modified type as long as it has characteristics that have been confirmed to be safe and physiologically active, but it is preferably a quality used for medical purposes. Standards that are secured are used in the minimum required amount.
- the concentration of cytoforce-in to be added is not particularly limited as long as it is a concentration at which rod-shaped cells are induced.
- the total concentration of cytoforce-ins is preferably about 10 to 1000 ng / mL, more preferably 20 to 500 ng / mL. About mL.
- Culturing can be carried out using a well-known medium usually used for culturing leukocytes.
- the culture temperature is not particularly limited as long as leukocyte growth is possible, but is most preferably about 37 ° C, which is the human body temperature.
- the gaseous environment during the culture is not particularly limited as long as leukocytes can grow, but 5% CO
- the culture period is not particularly limited as long as a necessary number of cells are induced, but it is usually performed for 3 days to 8 weeks.
- An appropriate device can be used for cell separation and culture, but it is preferable that safety is confirmed for medical use and that the operation is stable and simple.
- laminated containers, multistage containers, roller bottles, spinner bottles, bag-type incubators, hollow fiber columns, etc. can be used regardless of general containers such as petri dishes, flasks, and bottles. .
- the method of contacting the peptide of the present invention with an antigen-presenting cell in vitro can be performed by a well-known method, and is also specifically described in the following examples.
- antigen-presenting cells can be cultured by culturing them in a culture solution containing the peptide of the present invention.
- the peptide concentration in the medium is not particularly limited, but is usually about 1 ⁇ g / ml to 100 g / ml, preferably about 5 g / ml to 20 g / ml.
- the cell density at the time of culture is not particularly limited, but is usually about 10 3 cells / ml to 10 7 cells / ml, preferably 5xl04 4 cells / ml. About 5xl0 6 cells / ml. Cultivation should be performed in a 37 ° C, 5% CO atmosphere according to conventional methods.
- the peptide is taken up by the HLA molecule of the antigen-presenting cell and presented on the surface of the antigen-presenting cell.
- the present invention also provides an isolated antigen-presenting cell comprising such a complex of the peptide of the present invention and an HLA molecule.
- Such antigen-presenting cells present the peptide to T cells in vivo or in vitro, and induce and proliferate cytotoxic T cells specific for the peptide.
- cytotoxicity T specific to the peptide is obtained.
- Cells can be induced and grown. This can be performed by co-culturing the antigen-presenting cells and T cells in a liquid medium.
- the antigen-presenting cells can be suspended in a liquid medium, placed in a container such as a well of a microplate, and T cells are added thereto and cultured.
- the mixing ratio of antigen-presenting cells and T cells during co-cultivation is not particularly limited, but is usually about 1: 1 to 1: 100, preferably about 1: 5 to 1:20 in terms of the number of cells.
- the density of antigen-presenting cells suspended in the liquid medium is not particularly limited, but is usually about 1 to 10 million cells / ml, preferably about 10 to 10 million cells / ml. Co-cultivation should be performed in a 37 ° C, 5% CO atmosphere according to conventional methods.
- the culture time is not particularly limited, but is usually 2 days to 3 weeks, preferably about 4 days to 2 weeks.
- the coculture is preferably performed in the presence of one or more interleukins such as IL-2, IL-6, IL-7 and IL-12.
- the concentration of IL-2 and IL-7 is usually about 5U / ml to 20U / ml
- the concentration of IL-6 is usually about 500U / ml to about 2000U / ml
- the concentration of IL-12 is usually A force of about 5 ng / ml to 20 ng / ml is not limited to these.
- the above co-culture may be repeated once to several times by adding fresh antigen-presenting cells.
- the cocoon operation may be repeated once and several times.
- the conditions for each co-culture may be the same as described above.
- the peptide in order to present the peptide of the present invention on the surface of the antigen-presenting cell, the peptide is used as an anti-peptide. Adding to the culture medium of the original presentation cells is sometimes referred to as “pulsing cells with peptides”.
- contacting an antigen-presenting cell that presents the peptide of the present invention with a T cell may be referred to as “stimulating the T cell with a peptide”.
- cytotoxic T cells specific to the peptide are induced and propagated.
- the present invention also provides an isolated T cell that selectively binds the complex of the peptide of the present invention and an HLA molecule.
- the antigen-presenting cell presenting the peptide of the present invention can induce and proliferate a cytotoxic T cell specific for the peptide in vivo, and this is administered to the living body. Cancer treatment and Z or prevention.
- T cells that selectively bind a complex of the peptide of the present invention and an HLA molecule exhibit cytotoxic activity against cancer cells that express YKL-40, and thus the T cells are administered to a living body.
- Cancer treatment and Z or prevention can also be carried out.
- the present invention provides a medicament containing the antigen-presenting cell of the present invention as an active ingredient, a cancer treatment and Z or preventive agent, a medicament containing the T cell of the present invention as an active ingredient, and a cancer. Treatment and Z or preventive agents are also provided. Examples of cancers to be treated include, of course, cancers containing the peptide of the present invention as an active ingredient and the cancers mentioned above as targets for Z or prophylactic agents.
- Antigen presenting cells or T cells to be administered to a living body attack these cells as a foreign body
- the collected antigen presenting cells or ⁇ cells It is preferably prepared using the peptide of the present invention as described above.
- the therapeutic route for cancer containing an antigen-presenting cell or ⁇ cell as an active ingredient and the administration route of Z or a prophylactic agent are preferably parenteral administration such as intravenous administration or intraarterial administration.
- the dose is appropriately selected according to symptoms, purpose of administration, etc., but is usually 1 to 10 trillion, preferably 100 million to 1 billion, and this is 1 to several days to several months. Preferably, it is administered once.
- the formulation is
- the present invention further provides an antibody having the peptide of the present invention as a corresponding antigen and an antigen-binding fragment thereof.
- the antigen-binding fragment means an antibody fragment capable of binding to an antigen, such as a Fab fragment or F (ab ′) fragment contained in an antibody molecule.
- Antibody is polyclonal
- Either a monoclonal antibody or a monoclonal antibody may be used, but for the immunoassay, a monoclonal antibody is preferred because of its high reproducibility.
- Methods for preparing polyclonal and monoclonal antibodies using a peptide as an immunogen are well known and can be easily performed by conventional methods. For example, an antibody against a peptide can be induced by immunizing an animal together with an adjuvant using an immunogen obtained by binding a peptide to a keyhole limpet and a carrier protein such as mosyanin (KLH) or casein.
- KLH mosyanin
- Antibody-producing cells such as spleen cells and lymphocytes collected from immunized animals are fused with myeloma cells to prepare hybridomas that produce antibodies that bind to the peptides of the present invention.
- a monoclonal antibody having the peptide of the present invention as a corresponding antigen can be obtained by growing the culture supernatant. The above method is a well-known ordinary method.
- the antibody of the present invention or an antigen-binding fragment thereof can be used as an immunoassay reagent for detecting or quantifying cells expressing YKL-40 or antigen-presenting cells presenting the peptide of the present invention.
- Immunoassays themselves are well known in this field. When classified by reaction mode, there are a sandwich method, a competition method, an agglutination method, a Western plot method, etc., and flow cytometry can also be considered as one type of immunoassay.
- the antibody or antigen-binding fragment thereof of the present invention when classified by label, there are radioimmunoassay, fluorescence immunoassay, enzyme immunoassay, piotin immunoassay, etc., and the antibody or antigen-binding fragment thereof of the present invention can be used for these deviations.
- the antibody of the present invention or an antigen-binding fragment thereof When used for detecting or quantifying cells expressing YKL-40, the antibody of the present invention or an antigen-binding fragment thereof functions as a diagnostic agent for cancer.
- a sandwich ELISA or an agglutination method that is simple in operation and does not require a large-scale apparatus is preferable.
- the peptide of the present invention can also be used as an immunoassay reagent when detecting or measuring cells expressing the peptide by a competitive method.
- YKL-40 can be administered to a living body as a cancer-specific immunity inducer. That is, the present invention Cancer-specific immunity induction comprising as an active ingredient a protein having the amino acid sequence shown in SEQ ID NO: 2 or a protein having an amino acid sequence having 80% or more identity with the amino acid sequence and having immunity-inducing activity An agent is also provided.
- the administration route to the living body, the dosage, the preparation and the like may be the same as those of the cancer treatment and Z or prevention agent containing the above-mentioned peptide as an active ingredient.
- Example 1 Induction of YKL-40-derived peptide epitope reactive CD8 positive T cells
- Peripheral blood was isolated from a healthy person positive for HLA—A0201 and overlaid with Lymphocyte separation medium (OrganonpTeknika, Durham, NC), and centrifuged at 1,500 rpm at room temperature for 20 minutes. Fractions containing PBMC were collected and washed three times (or more) in cold phosphate buffer to obtain peripheral blood mononuclear cells (PBMC). The obtained PBMC was suspended in 20 ml of AIM-V medium (Lif e Technololgies, Inc., Grand Island, NY), and allowed to adhere to the culture flask (Falcon) for 2 hours under conditions of 37 ° C and 5% CO. . Non-adherent cells are used for T cell preparation.
- Lymphocyte separation medium OrganonpTeknika, Durham, NC
- the adherent cells were used to prepare rod cells.
- adherent cells were cultured in AIM-V medium in the presence of IL 4 (1000 UZml) and GM-CSF (10 OOUZml). 6 days later IL-4 (1000UZml), GM-CSF (100 0U / ml), IL-6 (1000U / ml, Genzyme, Cambridge, MA), IL-l j8 (lOng / ml, Genzyme, Cambridge, MA) The non-adherent cell population obtained after replacing with AIM-V medium supplemented with TNF- (lOngZ ml, Genzyme, Cambridge, MA) and further culturing for 2 days was used as the rod-shaped cells.
- the prepared rod cells are suspended in AIM V medium at a cell density of 1 ⁇ 10 6 cells Zml, and the selected peptide is added at a concentration of 10 / z gZml. Using 37 ° C, 5% The cells were cultured for 4 hours under CO conditions. After incubation, X-ray irradiation (3000 rad) and AIM-V medium
- AIM-V medium containing 10% human AB serum (Nabi, Miami, FL), IL-6 (lOOOUZml) and IL-12 (lOng / ml, Genzyme, Cambridge, MA), 24 wells 1 ⁇ 10 5 cells were added per well per plate. Further, the prepared T cell population was added with IX 10 6 cells per well and cultured under conditions of 37 ° C and 5% CO. 7 days later
- T2 cells expressing the HLA-A0201 molecule pulsed with the peptide (literature and source: Salter RD et al., Immunogenetics, 21: 235- 24 6 (1985), purchased from ATCC) (Add each peptide in AIM-V medium at a concentration of 10 ⁇ gZml and incubate at 37 ° C, 5% CO for 4 hours) 5 X 10 4 In contrast, 5 10 3 pieces
- the cells were added and cultured in 96-well plates for 24 hours in AIM-V medium containing 10% human AB serum. The supernatant after the culture was taken, and the amount of IFN-y produced was measured by ELISA. As a result, compared to the culture supernatant of the wells using T2 cells not pulsed with the peptide, the culture supernatants of the wells using T2 cells pulsed with the peptide of SEQ ID NO: 3! ⁇ production was confirmed. ( Figure 1).
- the peptide of SEQ ID NO: 3 has the ability to specifically stimulate HLA—A0201-positive CD8-positive sputum cells and induce IFN-y production. It was found to be a T cell epitope peptide.
- HLA-AO 201-positive CD8-positive T cells were specifically stimulated to proliferate and have the ability to induce IFN-y production. Five).
- reference number 1 on the vertical axis shows the results for the peptide having the amino acid sequence represented by SEQ ID NO: 3.
- Reference number 2 is one of YKL-40-derived peptides, but shows the results for peptide LQCCSAYKL (SEQ ID NO: 19) outside the scope of the present invention (Comparative Example 1).
- Reference number 3 shows the results when the above treatment was carried out without adding the peptide (Comparative Example 2).
- reference numbers 12 to 25 on the horizontal axis indicate the results for the peptide having the amino acid sequence shown in SEQ ID NO: 17, respectively.
- the reference number 26 on the horizontal axis is one of the peptides derived from YKL-40, but the results for the peptide of SEQ ID NO: 19 which is a peptide outside the scope of the present invention (Comparative Example 3), the reference number 27 on the horizontal axis is The results are shown when the above treatment is performed without adding the peptide (Comparative Example 4).
- the cytotoxic activity of CD8-positive T cell cells stimulated with the peptide of SEQ ID NO: 3 was calculated.
- cytotoxicity against HLA-A0201-positive CD8-positive T cell force T98G stimulated with this peptide ( Figure 2). Therefore, the peptide of SEQ ID NO: 3, which is one of the peptides of the present invention, is presented on the HLA-AO201 molecule on tumor cells that are HLA-A0201-positive and express YKL-40. Have been shown to be capable of inducing CD8 positive cytotoxic T cells that can damage such tumor cells.
- HLA-A0201-positive CD8-positive T cells stimulated with each of the 14 peptides shown in SEQ ID NO: 17 showed cytotoxic activity against T98G (FIG. 6).
- HLA-A0201-positive CD8-positive T cells stimulated with each of the 15 peptides shown in SEQ ID NO: 3 to SEQ ID NO: 17 are another malignant brain tumor cell line in which expression of YKL-40 is confirmed, Cytotoxic activity against U87 MG (Beckman G et al., Hum. Hered., 21: 238—241 (1971), purchased from ATCC) ( Figure 7)
- cytotoxic activity as described above, malignant brain tumor cell line T98G or 10 3 that has captured the CD8-positive T cells 10 5 and Kuromiumu 51 stimulated induced in each peptide of the invention Cultivate for 4 hours after mixing with U87 MG, measure the amount of chromium 51 released into the culture medium after culture, and determine the cytotoxic activity of CD8 positive T cells against T98G or U87 MG calculated by the following formula * It is the result shown.
- Cytotoxic activity (%) Chromium 51 release from T98G or U87 MG when CD8 positive T cells are added ⁇ Chromium 51 release from target cells containing 1N hydrochloric acid X 100
- reference numbers 28 to 41 on the horizontal axis represent the results for the peptides of SEQ ID NO: 4 to SEQ ID NO: 17, respectively.
- reference number 42 on the horizontal axis is a peptide derived from YKL-40, but the results of the peptide of SEQ ID NO: 19, which is a peptide outside the scope of the present invention (Comparative Example 5), refer to the horizontal axis.
- Number 43 shows the result when the above treatment was performed without adding the peptide (Comparative Example 6).
- reference numbers 44 to 58 on the horizontal axis indicate the results for the peptides of SEQ ID NO: 3 to SEQ ID NO: 17, respectively.
- reference number 59 on the horizontal axis is a result of the peptide of SEQ ID NO: 19 which is one of the peptides derived from YKL-40 but is outside the scope of the present invention (Comparative Example 7), and reference number on the horizontal axis. 60 shows the results when the above treatment was carried out without adding a peptide (Comparative Example 8).
- Example 3
- SYFPEITHI algorithm (Rammensee, et al., “Immunogenetics”, 1999, 50, p. 213-219, for predicting CD4-positive T cell antigen epitopes. ), ProPred algorithm ((Singh, 1 outside, “Bioinformatics”, 2001, Vol. 17, p. 1236—1237), and RAN KPEP algorithm (Reche, Two others, “Human i mmunology” was used to analyze the amino acid sequence of human YKL-40 protein using three computer prediction programs, and peptides that were predicted to be HLA class II-binding peptides were selected. .
- Peripheral blood was separated from a healthy person positive for HLA-DRB1 * 04, layered on Lymphocyte separation medium (OrganonpTeknika, Durham, NC), and centrifuged at 1,500 rpm at room temperature for 20 minutes. Fractions containing PBMC were collected and washed three times (or more) in cold phosphate buffer to obtain peripheral blood mononuclear cells (PBMC). The obtained PBMC was suspended in 20 ml of AIM-V medium (Life Technololgies, Inc., Grand Island, NY), and allowed to adhere to the culture flask (Falcon) for 2 hours under conditions of 37 ° C and 5% CO. . Non-adherent cells are used for T cell preparation
- Adherent cells were used to prepare rod-shaped cells.
- adherent cells were cultured in AIM-V medium in the presence of IL 4 (1000 UZml) and GM-CSF (10 OOUZml). 6 days later IL-4 (1000UZml), GM-CSF (100 0U / ml), IL-6 (1000U / ml, Genzyme, Cambridge, MA), IL-l j8 (lOng / ml, Genzyme, Cambridge, MA) The non-adherent cell population obtained after replacing with AIM-V medium supplemented with TNF- (lOngZ ml, Genzyme, Cambridge, MA) and further culturing for 2 days was used as the rod-shaped cells.
- the prepared rod-shaped cells are suspended in AIM-V medium at a cell density of 1 ⁇ 10 6 cells Zml, and the selected peptide is added at a concentration of lOmgZml, using a 96-well plate.
- the cells were cultured at 37 ° C and 5% CO for 4 hours. After incubation, X-ray irradiation (3000 rad) and washing with AIM-V medium
- AIM-V medium containing 10% human AB serum (Nabi, Miami, FL), IL-6 (lOOOUZml) and IL-12 (10 ng / ml, Genzyme, Cambridge, MA), 24 Hole pre 1 ⁇ 10 5 cells were added per well. Further, the prepared T cell population was added with IX 10 6 cells per well and cultured under conditions of 37 ° C. and 5% CO. 7 days later
- T cells stimulated with the peptide of SEQ ID NO: 18, which is the peptide of the present invention grew among the T cells in each well induced above.
- CD4-positive T cells 5 ⁇ 10 3 CD4-positive T cells were added and cultured in 96-well plates for 24 hours in AIM-V medium containing 10% human AB serum. The supernatant after culturing was taken and the amount of IFN-y produced was measured by ELISA. As a result, IFN-y of lOOOpgZml or more was produced in the culture supernatant of the wells using T2DR4 cells pulsed with the peptide of SEQ ID NO: 18 (FIG. 3). On the other hand, almost no IFN- ⁇ production was observed in the culture supernatant of the wells using other peptides and T2DR4 cells not pulsed with peptide (Fig. 3).
- the peptide of SEQ ID NO: 18 is a sputum cell epitope peptide having the ability to specifically stimulate HLA-DRB1 * 04 positive CD4 positive sputum cells to induce proliferation and induce IFN- ⁇ production.
- reference number 4 on the vertical axis shows the results for the peptide of the present invention having SEQ ID NO: 18.
- reference number 5 on the vertical axis is a result of the peptide of SEQ ID NO: 19 which is one of YKL-40 derived peptides but is outside the scope of the present invention (Comparative Example 7).
- Reference number 6 on the vertical axis shows the results when the above treatment was performed without adding peptide (Comparative Example 8).
- this peptideka YKL-40 protein which has the ability to stimulate proliferation of HLA-DRB1 * 04-positive T cells, is naturally processed in antigen-presenting cells and is displayed on HLA-DR.
- T cells stimulated with this peptide after the expression of YKL-40 has been confirmed and lysate of a malignant brain tumor cell line, T98G, is added to the immature rod cells and digested. Was stimulated by this rod cell. 1.
- a cell lysate was prepared by repeatedly freezing and thawing a pellet of 5 ⁇ 10 6 T98G cells 7 times using liquid nitrogen and a hot water bath.
- peripheral blood was separated from HLA-DRB1 * 04-positive healthy individuals, layered on Lymphocyte separation medium, and centrifuged at 1,500 rpm at room temperature for 20 minutes.
- the phase containing PBMC was harvested and washed 3 times (or more) in cold phosphate buffer to obtain PBMC.
- the obtained PBMCs were suspended in 20 ml of AIM-V medium, allowed to attach in a culture flask (Falcon) for 2 hours at 37 ° C and 5% CO, and adherent cells were treated with IL 4 (lOOOUZml in AIM-V medium).
- GM-CSF (lOOOUZml) was cultured for 6 days to produce immature rod cells. Each cell lysate was added to 5 x 10 5 immature rod cells and IL-4 (lOOOU / ml), GM-CSF (1 OOOU / ml), IL6 (1 OOOU / ml), IL The cells were cultured in AIM-V medium supplemented with 1 j8 (1 Ong / ml) and TNF-a (lOng / ml) for 2 days.
- immature rod cells added with the peptide of SEQ ID NO: 18 and immature rod cells supplemented with PBMC cell lysate (prepared from 1.5 ⁇ 10 6 cell pellets)
- AIM-V medium prepared with IL-4 (1000UZml), GM-CSF (lOOOUZml), IL-6 (1 OOOU / ml), IL-1 j8 (lOngZml) and TNF-a (lOngZml), respectively.
- IL-4 1000UZml
- GM-CSF GM-CSF
- IL-6 (1 OOOU / ml
- IL-1 j8 IL-1 j8
- TNF-a laOngZml
- Cells are irradiated with X-rays (3000 rad), washed with AIM-V medium, suspended in AIM-V medium containing 10% human AB serum, and 3.3 x 10 4 per 96-well plate. He added. These cells were supplemented with 5 ⁇ 10 4 T cells stimulated with 4 YKL peptides and cultured at 37 ° C. and 5% CO for 72 hours. Note that the culture start power was also 48 hours later.
- Tritium thymidine in lmCi units was added to the nutrient solution. After cultivation, use a cell harvester The cells were collected on glass filter paper, and the amount of tritium thymidine incorporated was measured with a liquid scintillation counter. As a result, as shown in FIG. 4, it was confirmed that T cells stimulated with the peptide of SEQ ID NO: 18 proliferated by stimulation of rod-shaped cells to which lysate of T98G cells was added. Furthermore, since these reactions are inhibited by the addition of an anti-HLA-DR neutralizing antibody, the peptide power YKL-40 protein of the present invention of SEQ ID NO: 18 is naturally processed in antigen-presenting cells. It became clear that it was an epitope presented on HLA-DR.
- reference number 7 on the vertical axis represents HLA-DRB1 * 04-positive rod-shaped cells pulsed with the peptide of the present invention of SEQ ID NO: 18 and HLA stimulated with the peptide.
- Tritium in CD4 positive T cells after mixing with DRB1 * 04 positive CD4 positive T cells and culturing in AIM-V medium containing 10% human AB serum for 48 hours, followed by further incubation for 24 hours The results showing the amount of thymidine incorporation are shown.
- Reference number 8 is an HLA-DRB1 * 04 positive rod-shaped cell that has been lysed with a malignant brain tumor cell line T98G, which has been irradiated with X-rays and stimulated with the peptide of the present invention of SEQ ID NO: 18.
- -In CD4 positive T cells after mixing with DRB1 * 04 positive CD4 positive T cells and cultivating them in AIM-V medium containing 10% human AB serum for 48 hours and then adding tritium thymidine for another 24 hours. The result which showed the uptake amount of tritium thymidine is shown.
- Reference number 9 shows the lysate of the malignant brain tumor cell line T98G incorporated into HLA-DRB1 * 04-positive rod cells irradiated with X-rays and the HLA stimulated with the peptide of the present invention of SEQ ID NO: 18.
- CD after mixing with tritiated thymidine for 48 hours in AIM-V medium containing 10% human AB serum and anti-HLA-DR antibody mixed with CD4 + T cells positive for CD-DR Bl * 04 The result which showed the uptake amount of tritium thymidine in 4 positive T cell is shown.
- Reference number 10 is an X-irradiated version of peripheral blood mononuclear cell lysate isolated from HLA-DRB1 * 04-positive healthy individuals, which was incorporated into HLA-DRB1 * 04-positive rod cells, and SEQ ID NO: 18.
- a mixture of HLA-DRB1 * 04-positive CD4 positive T cells stimulated with the peptide of the present invention and cultured in AIM-V medium containing 10% human AB serum for 48 hours, followed by addition of tritium thymidine for 24 hours The results showing the amount of tritiated thymidine incorporation in CD4-positive T cells after culturing are shown.
- Reference number 11 is associated with X-irradiated HLA-DRB1 * 04-positive rod cells.
- HLA-DRB1 * 04-positive CD4-positive T cells stimulated with the peptide of the present invention in column No. 18 were mixed and cultured in AIM-V medium containing 10% human AB serum for 48 hours, and then tritiated thymidine was added. Further, the results show the amount of tritiated thymidine taken up by CD4 positive T cells after 24 hours of culture.
- the peptide of the present invention is useful as an active ingredient for cancer treatment and Z or prevention agent, and is also useful for induction of antigen-presenting cells and ⁇ cells that can be used as cancer treatment and Z or prevention agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006546702A JP5087925B2 (ja) | 2004-12-07 | 2005-12-06 | 新規癌抗原ペプチド及びその用途 |
CN2005800418806A CN101072875B (zh) | 2004-12-07 | 2005-12-06 | 新型癌抗原肽及其用途 |
US11/792,400 US7902143B2 (en) | 2004-12-07 | 2005-12-06 | Cancer antigen peptide and the use thereof |
ES05814555.8T ES2534752T3 (es) | 2004-12-07 | 2005-12-06 | Nuevo péptido antigénico contra el cáncer y utilización del mismo |
EP05814555.8A EP1835027B1 (en) | 2004-12-07 | 2005-12-06 | Novel cancer antigen peptide and the use thereof |
CA2600898A CA2600898C (en) | 2004-12-07 | 2005-12-06 | Novel cancer antigen peptide and the use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004353820 | 2004-12-07 | ||
JP2004-353820 | 2004-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006062094A1 true WO2006062094A1 (ja) | 2006-06-15 |
Family
ID=36577921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/022369 WO2006062094A1 (ja) | 2004-12-07 | 2005-12-06 | 新規癌抗原ペプチド及びその用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7902143B2 (ja) |
EP (1) | EP1835027B1 (ja) |
JP (1) | JP5087925B2 (ja) |
CN (1) | CN101072875B (ja) |
CA (1) | CA2600898C (ja) |
ES (1) | ES2534752T3 (ja) |
WO (1) | WO2006062094A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008106052A (ja) * | 2006-09-26 | 2008-05-08 | Toray Ind Inc | 免疫誘導剤及びその用途 |
JP2011525108A (ja) * | 2008-06-20 | 2011-09-15 | コミッサリア ア レネルジ アトミック エ オー エネルジ アルターネイティブス | ミッドカインタンパク質に由来する抗ガンワクチンとしての免疫原性ペプチド |
US8580520B2 (en) | 2008-09-15 | 2013-11-12 | Herlev Hospital | YKL-40 as a marker for gastrointestinal cancers |
US8697384B2 (en) | 2008-01-23 | 2014-04-15 | Herlev Hospital | YKL-40 as a general marker for non-specific disease |
US8859488B2 (en) | 2004-09-21 | 2014-10-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
JP2016040290A (ja) * | 2009-09-03 | 2016-03-24 | 東レ株式会社 | 免疫誘導剤 |
US20160355550A1 (en) * | 2008-10-01 | 2016-12-08 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
US10485858B2 (en) | 2012-05-16 | 2019-11-26 | Stemline Therapeutics, Inc. | Cancer stem cell targeted cancer vaccines |
US10874730B2 (en) | 2004-09-21 | 2020-12-29 | University Of Pittsburgh—of The Commonwealth System | Methods for treating brain cancer using il-13r alpha 2 peptide-based compositions |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016204707B2 (en) * | 2008-10-01 | 2018-02-22 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
CN102597768B (zh) * | 2009-09-28 | 2015-01-07 | 希拉麦博股份有限公司 | 临床前测试免疫调节药物的方法 |
CN106520800A (zh) * | 2016-11-25 | 2017-03-22 | 南京医科大学第二附属医院 | 一种密码子优化的Chi3L1基因及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033739A1 (en) | 1995-04-25 | 1996-10-31 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
JP2000510106A (ja) * | 1996-04-24 | 2000-08-08 | アクゾ・ノベル・エヌ・ベー | 抗原特異的免疫抑制療法での使用に適した新規ペプチド |
JP2002525632A (ja) * | 1998-10-01 | 2002-08-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌の標識及び予後指標としてのykl−40 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3023469B2 (ja) * | 1992-02-21 | 2000-03-21 | 株式会社日本抗体研究所 | 糖タンパク質39遺伝子 |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
US6881824B1 (en) * | 1996-04-24 | 2005-04-19 | Akzo Nobel N.V. | Peptides suitable for use in antigen specific immunosuppressive therapy |
US5726061A (en) * | 1996-10-08 | 1998-03-10 | Smithkline Beechum Corporation | Method of diagnosing and monitoring colorectal cancer |
US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
-
2005
- 2005-12-06 US US11/792,400 patent/US7902143B2/en active Active
- 2005-12-06 ES ES05814555.8T patent/ES2534752T3/es active Active
- 2005-12-06 WO PCT/JP2005/022369 patent/WO2006062094A1/ja active Application Filing
- 2005-12-06 EP EP05814555.8A patent/EP1835027B1/en active Active
- 2005-12-06 JP JP2006546702A patent/JP5087925B2/ja active Active
- 2005-12-06 CA CA2600898A patent/CA2600898C/en active Active
- 2005-12-06 CN CN2005800418806A patent/CN101072875B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033739A1 (en) | 1995-04-25 | 1996-10-31 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
JP2000510106A (ja) * | 1996-04-24 | 2000-08-08 | アクゾ・ノベル・エヌ・ベー | 抗原特異的免疫抑制療法での使用に適した新規ペプチド |
JP2002525632A (ja) * | 1998-10-01 | 2002-08-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌の標識及び予後指標としてのykl−40 |
Non-Patent Citations (22)
Title |
---|
"Experimental Medicine", vol. 12, 1994 |
BECKMAN G ET AL., HUM. HERED., vol. 21, 1971, pages 238 - 241 |
BRUGGEN P. ET AL., SCIENCE, vol. 254, 1991, pages 1643 - 1647 |
COCHLOVIUS B ET AL: "In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program.", J IMMUNOL., vol. 165, no. 8, 2000, pages 4731 - 4741, XP002994562 * |
GODING: "Monoclonal Antibodies: Principles and Practice", 1986 |
INT. J. CANCER, vol. 58, 1994, pages 317 |
J. IMMUNOL., vol. 154, 1995, pages 2257 |
KAWAKAMI Y. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 6458 - 6462 |
KAWAKAMI Y. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, no. 9, 1994, pages 3515 - 3519 |
KREIG, NATURE, vol. 374, pages 546 - 549 |
MEENA K. ET AL., CANCER RES., vol. 62, 2002, pages 4364 - 4368 |
MOLECULES AND CELLS, vol. 7, 1997, pages 178 - 186 |
NIKKEI SCIENCE, April 1994 (1994-04-01), pages 20 - 45 |
RAMMENSEE, IMMUNOGENETICS, vol. 50, 1999, pages 213 - 219 |
ROBBINS P.F. ET AL., CANCER RES., vol. 54, 1994, pages 3124 - 3126 |
SALTER RD ET AL., IMMUNOGENETICS, vol. 21, 1985, pages 235 - 246 |
See also references of EP1835027A4 |
SINGH, BIOINFORMATICS, vol. 17, 2001, pages 1236 - 1237 |
STEIN GH ET AL., J. CELL PHYSIOL., vol. 99, 1979, pages 43 - 54 |
TANWAR M K ET AL: "Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.", CANCER RES., vol. 62, no. 15, 2002, pages 4364 - 4368, XP002994561 * |
THE PHARMACEUTICAL MONTHLY, vol. 36, no. 1, 1994, pages 23 - 48 |
TSUYOSHI AKIYOSHI, JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, vol. 24, 1997, pages 551 - 519 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10434155B2 (en) | 2004-09-21 | 2019-10-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
US11723963B2 (en) | 2004-09-21 | 2023-08-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
US10874730B2 (en) | 2004-09-21 | 2020-12-29 | University Of Pittsburgh—of The Commonwealth System | Methods for treating brain cancer using il-13r alpha 2 peptide-based compositions |
US8859488B2 (en) | 2004-09-21 | 2014-10-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
JP2008106052A (ja) * | 2006-09-26 | 2008-05-08 | Toray Ind Inc | 免疫誘導剤及びその用途 |
US8697384B2 (en) | 2008-01-23 | 2014-04-15 | Herlev Hospital | YKL-40 as a general marker for non-specific disease |
JP2011525108A (ja) * | 2008-06-20 | 2011-09-15 | コミッサリア ア レネルジ アトミック エ オー エネルジ アルターネイティブス | ミッドカインタンパク質に由来する抗ガンワクチンとしての免疫原性ペプチド |
US8580520B2 (en) | 2008-09-15 | 2013-11-12 | Herlev Hospital | YKL-40 as a marker for gastrointestinal cancers |
US20160355550A1 (en) * | 2008-10-01 | 2016-12-08 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
JP2017018101A (ja) * | 2008-10-01 | 2017-01-26 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
US10047123B2 (en) * | 2008-10-01 | 2018-08-14 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including neuronal and brain tumors |
JP2016040290A (ja) * | 2009-09-03 | 2016-03-24 | 東レ株式会社 | 免疫誘導剤 |
JP2021181464A (ja) * | 2010-08-24 | 2021-11-25 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | インターロイキン−13受容体α2ペプチド脳がんワクチン |
US10485858B2 (en) | 2012-05-16 | 2019-11-26 | Stemline Therapeutics, Inc. | Cancer stem cell targeted cancer vaccines |
US11672847B2 (en) | 2012-05-16 | 2023-06-13 | Stemline Therapeutics, Inc. | Cancer stem cell targeted cancer vaccines |
Also Published As
Publication number | Publication date |
---|---|
US7902143B2 (en) | 2011-03-08 |
CN101072875B (zh) | 2011-05-18 |
ES2534752T3 (es) | 2015-04-27 |
CA2600898A1 (en) | 2006-06-15 |
CN101072875A (zh) | 2007-11-14 |
CA2600898C (en) | 2016-08-23 |
EP1835027A1 (en) | 2007-09-19 |
JP5087925B2 (ja) | 2012-12-05 |
EP1835027B1 (en) | 2015-02-25 |
JPWO2006062094A1 (ja) | 2008-06-12 |
US20090214480A1 (en) | 2009-08-27 |
EP1835027A4 (en) | 2009-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5087925B2 (ja) | 新規癌抗原ペプチド及びその用途 | |
JP5962739B2 (ja) | 免疫誘導剤 | |
CN104873962B (zh) | 免疫诱导剂 | |
JP6112171B2 (ja) | 免疫誘導剤 | |
CN101952429A (zh) | Stat3表位肽 | |
KR101988895B1 (ko) | 면역 유도제 | |
JP5954174B2 (ja) | 免疫誘導剤 | |
JP5217502B2 (ja) | 癌の治療及び/又は予防剤 | |
JPWO2017026389A1 (ja) | 免疫誘導剤 | |
JP5673641B2 (ja) | 免疫誘導剤及びその用途 | |
JPWO2009054470A1 (ja) | 免疫誘導剤及びその用途 | |
JP5151349B2 (ja) | 免疫誘導剤及びその用途 | |
WO2016175309A1 (ja) | 免疫誘導剤 | |
CN117024522A (zh) | 针对pik3ca基因e545k突变的肿瘤新抗原多肽及其应用 | |
WO2017170365A1 (ja) | 免疫誘導剤 | |
CN108697757A (zh) | 免疫诱导剂 | |
WO2014015831A1 (zh) | 肿瘤抗原性多肽及其作为肿瘤疫苗的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006546702 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580041880.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005814555 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2600898 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2005814555 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11792400 Country of ref document: US |